- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT06247397
Effect van HIgh-flow-therapie bij langdurige zuurstoftherapie (HILOT)
Effect van HIgh-flow-therapie bij langdurige zuurstoftherapie (HILOT): een multicenter, op registers gebaseerd, gerandomiseerd klinisch onderzoek
This is a registry-based, randomized, controlled clinical trial of the effect of added high-flow oxygen therapy (using the device Lumis HFT) during one year in people with long-term oxygen therapy (LTOT) for chronic obstructive pulmonary disease (COPD) or interstitial lung disease (ILD).
Studie Overzicht
Toestand
Conditie
Interventie / Behandeling
Gedetailleerde beschrijving
This is a registry-based, randomized, controlled clinical trial of patients with LTOT for COPD or ILD recruited using the Swedish National Registry for Respiratory Failure (Swedevox) in collaboration with a research network within the Swedish Respiratory Society. The trial evaluates the effect of added high-flow oxygen therapy nighttime to the regular low-flow oxygen therapy compared with regular low-flow oxygen therapy alone up to one year.
The purpose of this project is to improve evidence-based treatment of people with chronic respiratory failure, currently about 2000 patients annually in Sweden, who have high risk of adverse events and mortality.
Studietype
Inschrijving (Geschat)
Fase
- Niet toepasbaar
Contacten en locaties
Studiecontact
- Naam: Magnus Ekström, MD, PhD
- Telefoonnummer: +46 0455731000
- E-mail: magnus.ekstrom@med.lu.se
Studie Locaties
-
-
-
Örebro, Zweden, 70185
- Werving
- Department of Heart, Lung and Clinical Physiology, Örebro University Hospital
-
Contact:
- Josefin Sundh, MD, PhD
-
-
Blekinge County
-
Karlskrona, Blekinge County, Zweden, 37185
- Werving
- Research Unit, Blekinge University of Technology
-
Contact:
- Magnus Ekström, MD, PhD
- E-mail: magnus.ekstrom@med.lu.se
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
- Age 40 years or older
- Ongoing LTOT: prescribed for at least 15 hours per day; and since at least 28 days as registered in Swedevox
- COPD or ILD as main underlying reason for LTOT
- Oxygen concentrator as stationary oxygen source in the home including night-time
- Body mass index (BMI) < 35 kg/m2
Exclusion Criteria:
- Current or previous treatment with home HFOT
- Current treatment with home mechanical ventilation
- Current treatment with home CPAP
- Hospitalized during the last 2 weeks
- Current smoking or contact with flames
- Self-reported average use of the LTOT < 15h per day (24 hours)
- PaCO2 (breathing air at rest) > 8 kPa
- Strong clinical suspicion of obstructive sleep apnea (OSA) or obesity-related hypoventilation syndrome (OHS) (as judged by the responsible staff)
- Inability to participate in the study procedures (as judged by the staff)
- Not eligible for continuing LTOT due to other reason (as judged by the staff)
- Expected survival less than 3 months (as judged by the staff)
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Experimenteel: High-flow oxygen therapy
Intervention arm |
Added high-flow oxygen therapy using the device Lumis HFT during nighttime and at the patient's discretion daytime, with the usual care (low-flow oxygen therapy) the rest of the time. |
|
Actieve vergelijker: Low-flow oxygen therapy
Comparison arm |
Standard care with low-flow oxygen therapy in accordance with clinical routine. |
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Time to first hospitalization or death from all causes
Tijdsspanne: 1 year
|
Time to first hospitalization or death from all causes during 1 year after randomization in people with COPD (assessed using nationwide registry data) |
1 year
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Time to first all-cause hospitalization or all-cause death
Tijdsspanne: 1 year
|
Time to first all-cause hospitalization or all-cause death in people with ILD (assessed using nationwide registry data) |
1 year
|
|
Rate of hospitalizations or death from all causes
Tijdsspanne: 1 year
|
Rate of hospitalizations or death from all causes assessed using nationwide registry data |
1 year
|
|
Hospitalization rate from all causes
Tijdsspanne: 1 year
|
Hospitalization rate from all causes assessed using nationwide registry data |
1 year
|
|
Hospitalization rate from respiratory disease
Tijdsspanne: 1 year
|
Hospitalization rate from respiratory disease assessed using nationwide registry data |
1 year
|
|
Number of hospitalized days
Tijdsspanne: 1 year
|
Number of hospitalized days from all-causes, respiratory and cardiovascular disease using nationwide registry data |
1 year
|
|
Hospitalization rate from cardiovascular disease
Tijdsspanne: 1 year
|
Hospitalization rate from cardiovascular disease assessed using nationwide registry data |
1 year
|
|
Number of admissions to intensive care unit (ICU)
Tijdsspanne: 1 year
|
Number of admissions to ICU assessed using nationwide registry data |
1 year
|
|
Number of days in ICU
Tijdsspanne: 1 year
|
Number of days in ICU assessed using nationwide registry data |
1 year
|
|
Mortality rate from all causes
Tijdsspanne: 1 year
|
The mortality rate from all causes assessed using nationwide registry data |
1 year
|
|
Mortality rate from respiratory disease
Tijdsspanne: 1 year
|
The mortality rate from respiratory disease assessed using nationwide registry data |
1 year
|
|
Mortality rate from cardiovascular disease
Tijdsspanne: 1 year
|
The mortality rate from cardiovascular disease assessed using nationwide registry data |
1 year
|
|
Time to first exacerbation
Tijdsspanne: 1 year
|
Time to first exacerbation after randomisation, defined as time to first dispensed antibiotics and/or oral corticosteroids, ED-visit or hospitalization for exacerbation assessed using self-reported and registry data |
1 year
|
|
Number of exacerbations
Tijdsspanne: 1 year
|
Number of exacerbations of all severity assessed using self-reported and registry data |
1 year
|
|
Incidence of cardiovascular disease
Tijdsspanne: 1 year
|
Incidence of cardiovascular disease assessed using nationwide registry data |
1 year
|
|
Need for home mechanical ventilation
Tijdsspanne: 1 year
|
Need for starting home mechanical ventilation assessed using nationwide registry data |
1 year
|
|
Rate of withdrawal of long-term oxygen therapy
Tijdsspanne: 1 year
|
Rate of withdrawal of long-term oxygen therapy assessed using nationwide registry data |
1 year
|
|
Adverse events
Tijdsspanne: 3 and 12 months
|
Self-reported adverse events since study start assessed using a postal questionnaire. |
3 and 12 months
|
|
Primary care utilization
Tijdsspanne: 1 year
|
Self-reported number of primary care contacts since the start of the study assessed using a postal questionnaire. |
1 year
|
|
Health-related quality of life
Tijdsspanne: 3 and 12 months
|
Self-reported health-related quality of life assessed using the EuroQol Five Dimensions - Five Levels (EQ5D-5L) questionnaire. |
3 and 12 months
|
|
Health status
Tijdsspanne: 3 and 12 months
|
Self-reported health status assessed using the and the COPD Assessment Test (CAT) questionnaire. |
3 and 12 months
|
|
Breathlessness at exertion
Tijdsspanne: 3 and 12 months
|
Self-reported exertional breathlessness assessed using the Dyspnoea Exertion Scale (DES) questionnaire. |
3 and 12 months
|
|
Breathlessness
Tijdsspanne: 3 and 12 months
|
Self-reported breathlessness assessed using the Dyspnea-12 questionnaire. |
3 and 12 months
|
|
Sleep quality
Tijdsspanne: 3 and 12 months
|
Self-reported sleep quality assessed using the modified Basic Nordic Sleep Questionnaire. |
3 and 12 months
|
|
Physical activity
Tijdsspanne: 3 and 12 months
|
Self-reported level of physical activity assessed using the modified Grimby-Frändin questionnaire. |
3 and 12 months
|
|
Change in health status
Tijdsspanne: 3 and 12 months
|
Self-reported change in perceived health status assessed using the Global Impression of Change (GIC) scale. |
3 and 12 months
|
|
Nasal symptoms
Tijdsspanne: 3 and 12 months
|
Self-reported nasal symptoms assessed using the modified Björklund questionnaire. |
3 and 12 months
|
Andere uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Patient preference for continuing the treatment
Tijdsspanne: 3 and 12 months
|
Patients' self-reported patient preference for continuing the treatment assessed using postal questionnaire. |
3 and 12 months
|
Medewerkers en onderzoekers
Sponsor
Medewerkers
Onderzoekers
- Hoofdonderzoeker: Magnus Ekström, MD, PhD, Skane University Hospital
Publicaties en nuttige links
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Geschat)
Studie voltooiing (Geschat)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- HILOT
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Beschrijving IPD-plan
IPD cannot be shared due to restrictions in the current ethical approval. Pseudonymized IPD can be shared upon reasonable request and separate ethical approval.
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .